The purpose of this study is to see whether adding durvalumab to standard chemotherapy will improve overall survival (OS) in patients with MPM.
Durvalumab (MEDI4736) with chemotherapy as first line treatment in advanced pleural Mesothelioma - A phase 3 Randomised trial.
|Eligibility criteria|| |
Untreated stage IV Mesothelioma, please enquire for more details.
|Study details|| |
The treatment is comparing standard of care chemotherapy to chemotherapy with Atezolizumab, the study is randomised with a ratio of 2:1. While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.
|Further information|| |
For more information regarding this clinical trial click here.
North Shore NSW